Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...

The company said last month that it expected to report sales of diabetes drug Mounjaro and weight-loss treatment Zepbound ...

The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug ...

US stock futures fell on Wednesday after disappointing earnings from Alphabet, while the dollar took a dive against the yen, which rallied sharply after Japanese wage data upped the chances of another ...

EUROPEAN shares ended Wednesday’s choppy session higher, as a rise in healthcare companies GSK and Novo Nordisk following ...

US imports surged to a record high in December, official figures showed today as Donald Trump’s threat of tariffs triggered a rush among American companies to import goods.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

European shares saw a rise driven by healthcare giants GSK and Novo Nordisk following robust quarterly results. Novo Nordisk's strong profits from its drug Wegovy and GSK's share buyback plan boosted ...

Novo Nordisk (NVO), the maker of the popular GLP-1 medications Wegovy and Ozempic, said potential tariffs on Europe imposed ...